Efficacy and Safety Study of Elagolix Versus Placebo or Leuprorelin Acetate in Endometriosis
Status:
Completed
Trial end date:
2010-02-24
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the safety and beneficial effects of elagolix (NBI-56418)
compared to placebo and leuprorelin (an approved endometriosis therapy) over a three month
period followed by an additional three months of treatment on elagolix.